NANOGP8 antibody Polyclonal Antibodies Primary antibodies
- Known as:
- NANOGP8 (anti-) Polyclonal Antibodies Primary antibodies
- Catalog number:
- orb100546
- Product Quantity:
- 100
- Category:
- -
- Supplier:
- Biorb
- Gene target:
- NANOGP8 antibody Polyclonal Antibodies Primary antibodies
Related genes to: NANOGP8 antibody Polyclonal Antibodies Primary antibodies
- Gene:
- NANOGP8 NIH gene
- Name:
- Nanog homeobox retrogene P8
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 15q14
- Locus Type:
- gene with protein product
- Date approved:
- 2003-10-07
- Date modifiied:
- 2017-11-02
Related products to: NANOGP8 antibody Polyclonal Antibodies Primary antibodies
Related articles to: NANOGP8 antibody Polyclonal Antibodies Primary antibodies
- Initially, pseudogenes were considered to be "junk DNA", and their biological role was unclear. However, some of the pseudogenes are engaged in the process of cancerogenesis and perform essential functions in competing for endogenous ribonucleic acid (ceRNA) networks and competing for RNA binding proteins (RBPs). They either positively or negatively regulate gene expression and act as suppressive and oncogenic transcripts. In this review, we look at some of the pseudogenes that play a role in the epithelial-to-mesenchymal transition (EMT) process and the maintenance of cancer-initiating cells (CIC), which are essential in understanding cancer development and progression metastasis and resistance to commonly used therapies. The group of discussed pseudogenes consists of , , , , , or , which are connected with different molecular pathways. Moreover, we discussed pseudogenes as potential diagnostic molecules that can be used as a new class of biomarkers. This potential usage may be valuable for oncology and personalized medicine in the future. - Source: PubMed
Publication date: 2025/08/07
Kolenda TomaszChałaj PiotrCichowicz AleksandraTrojańska AleksandraBałoniak AndrzejKwaśniewska MalwinaOdrobińska MagdaGuglas KacperKozłowska-Masłoń JoannaGieremek PaulinaPoter PaulinaJaniczek-Polewska MarlenaFlorczak-Substyk AnnaPrzybyła AnnaMantaj PatrycjaRegulska KatarzynaStanisz Beata JadwigaCybulski ZefirynKazimierczak Urszula - Glioblastoma (GB) is the most common brain malignancy occurring in adult patients having an extremely low overall survival. Therefore, it is paramount to establish reliable and accurate diagnostic and prognostic markers to guide a personalized and more effective treatment. Molecular characterization of the tumor is the ultimate goal in GB management and comprises, among others, the study of the extracellular vesicles (EVs). Not only do they carry within their cargo molecules involved in shaping a favorable microenvironment for GB development, but EVs also present surface markers mirroring the phenotype of the donor cells. Our study aims to assess the dynamic evolution of EV-positive surface biomarkers and EV-derived proteins involved in maintaining and transferring a stem cell phenotype to the cells from GB surroundings. We performed a prospective observational study on GB patients operated on in the Neurosurgery Clinic of the Emergency Clinical County Hospital of Târgu Mureș, Romania. GB-derived EVs were isolated from the patients' plasma using a density gradient ultracentrifugation protocol. The expression of EVs positive to four epitopes specific to stem cells (CD44, CD133, CD326/EpCAM, and SSEA4) was followed in three moments in time, preoperatively, seven days, and three months postoperatively, respectively, and quantified by a bead-based multiple analysis using flow cytometry. Moreover, NANOGP8, a protein within GB cargo capable of promoting a stem cell phenotype, was dynamically evaluated using the Western blot technique. Our study showed a statistically significant decrease of all surface markers and NANOGP8 immediately after tumor ablation. Nonetheless, the long-term follow-up of the patients revealed an extremely variable evolutionary pattern reflecting the high heterogeneity of GB. Further studies are necessary to either confirm or infirm the accuracy of these markers in early diagnosing GB, in predicting the outcome of this disease, and in guiding an individualized therapy. - Source: PubMed
Publication date: 2024/09/28
Serban Georgiana MDoina ManuBalasa RodicaBalasa Adrian F - Extracellular vesicles (EVs) are garnering attention as a safe and efficient biomolecule delivery system. EVs intrinsically play a crucial role in intercellular communication and pathophysiology by transporting functionally active DNA molecules. The internalized DNA pleiotropically affects the recipient cells. Considering these salient features, an intentional incorporation of specific DNA gene cassettes into EVs and their subsequent delivery to the target cells has potential applications in genetic engineering. Moreover, efficient ways to insert the DNA into EVs during their biogenesis is valuable. Our current research is a step in the development of this technology. As such, cancer cells are known to secrete exosomes containing increased amounts of double-stranded DNA than normal cells. The clonal analysis in our previously published data revealed that exosomes released from various cancer cells contained a significantly larger population of NANOGP8 DNA with a 22-base pair insertion in the 3'-untranslated region (UTR) compared to those secreted by normal cells. This finding led us to hypothesize that the 22-base pair insertion may act as a signal to facilitate the incorporation of NANOGP8 DNA into the exosomes. To test this hypothesis, we compared the EV localization of an Enhanced Green Fluorescent Protein (EGFP) gene fused with the NANOGP8 3'-UTR, with and without the 22-base pair insertion. The quantitative PCR analysis showed a significantly higher EGFP DNA accumulation in exosomes released from cells transfected with the gene cassette containing the 3'-UTR with the 22-base pair insertion. The discovery of a DNA localization signal in exosomal DNA's 3'-UTR could pave the way for the development of an EV-based DNA delivery system. This technology will open new possibilities in genetic engineering and innovative therapies using nucleic acid medicine. - Source: PubMed
Publication date: 2024/07/02
Vaidya ManjushaKimura AyakaBajaj ArjunSugaya Kiminobu - Colon cancer (CC) stem cells can self-renew as well as expand, thereby promoting tumor progression and conferring resistance to chemotherapeutic agents. The acetyltransferase NAT10 mediates N4-acetylcytidine (acC) modification, which in turn drives tumorigenesis, metastasis, stemness properties maintenance, and cell fate decisions. Nonetheless, the specific involvement of acC modification mediated by NAT10 in regulating stemness and chemosensitivity in CC remains undetermined. - Source: PubMed
Publication date: 2024/04/25
Gao Li-PingLi Ting-DongYang Su-ZhenMa Hui-MinWang XiangZhang De-Kui - Exosomes participate in intercellular communication by transporting functionally active molecules. Such cargo from the original cells comprising proteins, micro-RNA, mRNA, single-stranded (ssDNA) and double-stranded DNA (dsDNA) molecules pleiotropically transforms the target cells. Although cancer cells secrete exosomes carrying a significant level of DNA capable of modulating oncogene expression in a recipient cell, the regulatory mechanism is unknown. We have previously reported that cancer cells produce exosomes containing NANOGP8 DNA. NANOGP8 is an oncogenic paralog of embryonic stem cell transcription factor NANOG and does not express in cells since it is a pseudogene. However, in this study, we evaluated NANOGP8 expression in glioblastoma multiforme (GBM) tissue from a surgically removed brain tumor of a patient. Significantly higher NANOGP8 transcription was observed in GBM cancer stem cells (CSCs) than in GBM cancer cells or neural stem cells (NSCs), despite identical sequences of NANOGP8-upstream genomic region in all the cell lines. This finding suggests that upstream genomic sequences of NANOGP8 may have environment-dependent promoter activity. We also found that the regulatory sequences upstream of exosomal NANOGP8 GBM DNA contain multiple core promoter elements, transcription factor binding sites, and segments of human viruses known for their oncogenic role. The exosomal sequence of NANOGP8-upstream GBM DNA is different from corresponding genomic sequences in CSCs, cancer cells, and NSCs as well as from the sequences reported by NCBI. These sequence dissimilarities suggest that exosomal NANOGP8 GBM DNA may not be a part of the genomic DNA. Exosomes possibly acquire this DNA from other sources where it is synthesized by an unknown mechanism. The significance of exosome-bestowed regulatory elements in the transcription of promoter-less retrogene such as NANOGP8 remains to be determined. - Source: PubMed
Publication date: 2023/01/25
Vaidya ManjushaSmith JonhoiField MelvinSugaya Kiminobu